Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study

被引：1
|
作者：
Fuereder, T. [1 ]
Minichsdorfer, C. [1 ]
Mittlboeck, M. [2 ]
Wagner, C. [1 ]
Oberndorfer, F. [3 ]
Mullauer, L. [3 ]
Aretin, M-B. [4 ]
Czerny, C. [5 ]
Schwarz-Nemec, U. [5 ]
机构：
[1] Med Univ Vienna, Vienna Gen Hosp, Internal Med I, Vienna, Austria
[2] Med Univ Vienna, Vienna Gen Hosp, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[3] Med Univ Vienna, Vienna Gen Hosp, Pathol, Vienna, Austria
[4] Vienna Gen Hosp, Pharm, Vienna, Austria
[5] Med Univ Vienna, Vienna Gen Hosp, Biomed Imaging & Image Guided Therapy, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
921P
引用
收藏
页码：S665 / S665
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
    Fuereder, Thorsten
    Minichsdorfer, Christoph
    Mittlboeck, Martina
    Wagner, Christina
    Heller, Gerwin
    Putz, Eva M.
    Oberndorfer, Felicitas
    Mullauer, Leonhard
    Aretin, Marie-Bernadette
    Czerny, Christian
    Schwarz-Nemec, Ursula
    ORAL ONCOLOGY, 2022, 124
  • [2] CETUXIMAB PLUS DOCETAXEL AS TREATMENT FOR RECURRENT AND/OR METASTATIC HEAD AND NECK CANCER
    Knoedler, M. K.
    Gauler, T. C.
    Matzdorff, A.
    Jordan, O.
    Schroeder, M.
    Gruenwald, V.
    Dietz, A.
    Hennemann, B.
    Arnold, D.
    Keilholz, U.
    ANNALS OF ONCOLOGY, 2008, 19 : 220 - 220
  • [3] Weekly chemotherapy with cisplatin and docetaxel for recurrent metastatic head and neck cancer: a phase II study
    Guntinas-Lichius, O.
    Appenrodt, S.
    Veelken, F.
    Krug, B.
    EJC SUPPLEMENTS, 2005, 3 (02): : 297 - 297
  • [4] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck - A phase II multicenter study
    Labourey, Jean-Luc
    Cupissol, Didier
    Calais, Gilles
    Tourani, Jean-Marc
    Kohser, Frederic
    Borel, Christian
    Eymard, Jean-Christophe
    Germann, Nathalie
    Tubiana-Mathieu, Nicole
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 278 - 282
  • [5] Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Gedlicka, C
    Formanek, M
    Selzer, E
    Burian, M
    Kornfehl, J
    Fiebiger, W
    Cartellieri, M
    Marks, B
    Kornek, GV
    ONCOLOGY, 2002, 63 (02) : 145 - 150
  • [6] Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer
    Guntinas-Lichius, O
    Appenrodt, S
    Veelken, F
    Krug, B
    LARYNGOSCOPE, 2006, 116 (04): : 613 - 618
  • [7] Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Yan, Q.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S855 - S856
  • [8] Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer
    Sheth, Siddharth
    Weiss, Jared
    FUTURE ONCOLOGY, 2018, 14 (16) : 1547 - 1558
  • [9] Phase II study of rubitecan in recurrent or metastatic head and neck cancer
    Francesco Caponigro
    Giacomo Cartenì
    Jean Pierre Droz
    Amalia Milano
    Wayne B. Davis
    Patricia Pollard
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 209 - 214
  • [10] Phase II study of rubitecan in recurrent or metastatic head and neck cancer
    Caponigro, Francesco
    Carteni, Giacomo
    Droz, Jean Pierre
    Milano, Amalia
    Davis, Wayne B.
    Pollard, Patricia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (02) : 209 - 214
12345